Project Overview
Advancing a Vaccine for Adolescent/Adult and Neonatal TB Epidemic.
- Duration: 1 May 2026 – 30 April 2030
- Funded by the European Union under GH-EDCTP3 & Biofabri
- Coordinated by Biofabri
- Partners – Biofabri, IAVI, TBVI, ECF, IHI, KEMRI, SATVI, UCT Lung Institute, Wits VIDA, UniZar
Between 2026 and 2030, MTBVAC AVANTE is working to accelerate the clinical development and access planning of MTBVAC to demonstrate its use as a safe, effective, and accessible vaccine to prevent TB in newborns, adolescents, and adults.
Under the name Advancing a Vaccine for Adolescent/Adult and Neonatal TB Epidemic (MTBVAC-AVANTE), the 12-partner consortium is supporting the expansion and completion of two major ongoing clinical trials alongside important concurrent and post-trial activities to lay the ground for more rapid country introductions of MTBVAC, should it be found safe and effective. For more information about this project, click here.
Consortium Partners & Coördinator
International Aids Vaccine Initiative (IAVI), the Netherlands, South Africa, Kenya, United States
TuBerculosis Vaccine Initative (TBVI),
the Netherlands
Enhancing Care Foundation (ECF) South Africa
Publications & News
Acknowledgement
